Role of monocytes in the expansion of human activated natural killer cells.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Blood

• Publication date

  1992-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V80.9.2221.BLOODJOURNAL8092221PMID 1421393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Feeder cells enhance oncolytic and proliferative activity of long-term human bone marrow interleukin-2 cultures and induce different lymphocyte subsets

  2005cited by this paper
• Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.

  1991cited by this paper
• Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.

  1991cited by this paper
• Fc gamma RIII (CD16) on human macrophages is a functional product of the Fc gamma RIII-2 gene.

  1991cited by this paper
• Inhibitory effect of monocytes on "lymphokine activated killer" (LAK) cell activity.

  1991cited by this paper
• FcγRIII (CD16) on human macrophages is a functional product of the FcγRIII‐2 gene

  1991cited by this paper
• Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.

  1991cited by this paper
• Biology and clinical relevance of human natural killer cells.

  1990cited by this paper
• Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.

  1990cited by this paper
• In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats

  1990cited by this paper
• Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

  1990cited by this paper
• A Cell‐to‐Cell Mediated Interaction Involving Monocytes and Non‐T/CD16+ Natural Killer (NK) Cells is Required for Histamine H2‐Receptor‐Mediated NK‐Cell Activation

  1990cited by this paper
• Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells.

  1990cited by this paper
• Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.

  1990cited by this paper
• Monocyte‐Mediated Suppression of IL‐2‐Induced NK‐Cell Activation

  1990cited by this paper
• Immunoregulatory role of in vitro differentiated macrophages on human natural killer (NK)-cell activity.

  1990cited by this paper
• Differential expression of CD8α and CD8β associated with MHC-restricted and non-MHC-restricted cytolytic effector cells

  1990cited by this paper
• Successful Adoptive Immunotherapy of Established Lung and Liver Metastases with Highly Purified IL-2-Activated Natural Killer Cells (A-LAK Cells)

  1990cited by this paper
• In vitro Generation and in vivo Effects of Adherent Lymphokine-Activated Killer Cells and IL2 in Patients with Solid Tumors1

  1990cited by this paper
• Killing of Alveolar Macrophages and of Monocytes that Have Responded to Granulocyte‐Macrophage Colony‐stimulating Factor by Human Lymphokine‐activated Killer Cells

  1989cited by this paper
• Lymphokine‐activated Killer Induction and Its Regulation by Macrophages in Malignant Pleural Effusions

  1989cited by this paper
• Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.

  1989cited by this paper
• Generation and characterization of purified adherent lymphokine-activated killer cells in mice.

  1989cited by this paper
• Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias.

  1989cited by this paper
• Activation of cloned human natural killer cells via Fc gamma RIII.

  1989cited by this paper
• Human lymphokine-activated killer (LAK) cells

  1989cited by this paper
• Comparative studies of human FcRIII-positive and negative natural killer cells.

  1989cited by this paper
• Lysis of human monocytes by lymphokine-activated killer cells.

  1988cited by this paper
• Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes.

  1988cited by this paper
• Role of natural killer cells in defense against leukemia: therapeutic considerations.

  1988cited by this paper
• Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells

  1988cited by this paper
• A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

  1988cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors.

  1987cited by this paper
• Monocyte‐dependent induction of proliferation of human peripheral T cells by recombinant interleukin 2

  1986cited by this paper
• Monocyte-mediated augmentation of human natural killer cell activity: conditions, monocyte and effector cell characteristics.

  1986cited by this paper

• A Novel Natural Killer Cell Expansion Technology for the Development of Cellular Immunotherapies

  2026cites this paper
• Single-Cell Transcriptomics Reveals Dynamics of NK Cell Expansion in a Feeder Cell-Free Culture of PBMCs - Implications for Immunotherapy

  2025cites this paper
• Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial

  2025cites this paper
• Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy.

  2025cites this paper
• N-803, an IL-15 superagonist complex as maintenance therapy after allogeneic donor stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome; a Phase 2 trial.

  2024cites this paper
• Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies

  2024cites this paper
• Osteoclasts and Probiotics Mediate Significant Expansion, Functional Activation and Supercharging in NK, γδ T, and CD3+ T Cells: Use in Cancer Immunotherapy

  2024cites this paper
• Natural killer cell‐related anti‐tumour adoptive cell immunotherapy

  2024cites this paper
• A review and statistical analysis to identify and describe relationships between CQAs and CPPs of natural killer cell expansion processes.

  2024cites this paper
• CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future.

  2023cites this paper
• CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.

  2022cites this paper
• CAR-NK cells for cancer immunotherapy: from bench to bedside

  2022cites this paper
• CAR-NK Cells in the Treatment of Solid Tumors

  2021influential citation
• Generating natural killer cells for adoptive transfer: expanding horizons.

  2021cites this paper
• NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas

  2021cites this paper
• Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance.

  2021cites this paper
• Current progress in NK cell biology and NK cell-based cancer immunotherapy

  2020cites this paper
• Antigen-independent killer cells prepared for adoptive immunotherapy: One source, divergent protocols, diverse nomenclature.

  2020cites this paper
• Manufacturing of natural killer cells for treating solid malignancies

  2020cites this paper
• First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

  2019cites this paper
• Delayed IL-21 treatment preferentially expands peptide-specific CD8+ T cells by reducing bystander activation of T cells.

  2019cites this paper
• CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15– and IL-21–Driven NK Cell Proliferation

  2019cites this paper
• The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation

  2019cites this paper
• Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity.

  2019cites this paper
• Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells

  2018cites this paper
• Clinical‐scale production of cGMP compliant CD3/CD19 cell‐depleted NK cells in the evolution of NK cell immunotherapy at a single institution

  2018cites this paper
• Differences in activation and tissue homing markers of natural killer cell subsets during acute dengue infection

  2018cites this paper
• The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction

  2018cites this paper
• Natural Killer Cells: What Have We Learned?

  2018cites this paper
• An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells

  2018cites this paper
• NK Cell Subsets in Health and Disease: New Developments

  2017cites this paper
• Influence of Irradiated Peripheral Blood Mononuclear Cells on Both Ex Vivo Proliferation of Human Natural Killer Cells and Change in Cellular Property

  2017cites this paper
• Clinical Applications of Natural Killer Cells

  2017cites this paper
• Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody

  2017cites this paper
• Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation

  2017cites this paper
• Manufacturing Natural Killer Cells as Medicinal Products

  2016cites this paper
• Proliferation of Highly Functional Human Expanded Natural Killer Cells by Osteoclasts for Cancer Immunotherapy Against OSCSCs

  2016cites this paper
• NCR1 is an activating receptor expressed on a subset of canine NK cells.

  2016cites this paper
• Mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation

  2016cites this paper
• The antileukemic potential of natural killer cells.

  2016cites this paper
• Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells

  2016cites this paper
• Silent IL2RG Gene Editing in Human Pluripotent Stem Cells.

  2016cites this paper
• Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

  2015cites this paper
• Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients

  2015cites this paper
• Use of Natural Killer Cells for Acute Leukemia Patients

  2015cites this paper
• Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies

  2015cites this paper
• Expansion of Highly Cytotoxic Human Natural Killer Cells by Osteoclast for Cancer Immunotherapy

  2015cites this paper
• Development of Cytotoxic Natural Killer Cells for Ovarian Cancer Treatment

  2015cites this paper
• A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

  2015cites this paper
• Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity

  2015cites this paper
• Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

  2014cites this paper
• Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line

  2014cites this paper
• cells is improved using IL-2 diphtheria toxin fusion protein Clearance of acute myeloid leukemia by haploidentical natural killer

  2014cites this paper
• Cellular therapy of cancer with natural killer cells-where do we stand?

  2013cites this paper
• GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer Cells In Vitro and In Vivo

  2013cites this paper
• signals and induces specific killing of leukemic cells Genetic modification of primary natural killer cells overcomes inhibitory

  2013cites this paper
• Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products

  2013cites this paper
• leukemias maturation of normal myelomonocytic cells but are low in acute myeloid Ligands for natural killer cell activating receptors are expressed upon

  2013cites this paper
• Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers.

  2013cites this paper
• Isolation and characterization of canine natural killer cells.

  2013cites this paper
• Targeted Cancer Therapy by Dendritic Cell Vaccine

  2013cites this paper
• Successful “in‐flight” activation of natural killer cells during long‐distance shipping

  2013cites this paper
• Natural killer cell reprogramming with chimeric immune receptors.

  2013cites this paper
• efficiently lysed by dimers of monovalent antibody Human T cells resistant to complement lysis by bivalent antibody can be

  2013cites this paper
• Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.

  2013cites this paper
• Natural killer cells: a review of manufacturing and clinical utility

  2013cites this paper
• Short title: Complement lysis by dimers of monovalent antibody Manuscript Category: Regular manuscript Scientific Section Heading: Immunobiology

  2013cites this paper
• Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines

  2012cites this paper
• haploidentical NK cells in cancer patients Successful adoptive transfer and in vivo expansion of human

  2012cites this paper
• Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T‐cell lymphoma cells by cell contact‐dependent interaction through membrane‐bound IL‐15

  2012cites this paper
• Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

  2012cites this paper
• Clinical production and therapeutic applications of alloreactive natural killer cells.

  2012cites this paper
• A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

  2011cites this paper
• Natural killer cell engineering for cellular therapy of cancer.

  2011cites this paper
• Expression and functional role of chemokines in nasal natural killer/T-cell lymphoma

  2011cites this paper
• Allogeneic natural killer cells for refractory lymphoma

  2010cites this paper
• Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity

  2010cites this paper
• Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy.

  2010cites this paper
• Biology and clinical effects of natural killer cells in allogeneic transplantation

  2010cites this paper
• Multipotent Human Progenitors In Vitro The Myeloid-Lymphoid Initiating Cell (ML-IC) Assay Assesses the Fate of

  2010cites this paper
• Clinical trials of NK cells for cancer

  2010cites this paper
• Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy

  2009cites this paper
• Expansion and activation of natural killer cells for cancer immunotherapy.

  2009cites this paper
• Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

  2009cites this paper
• Replicative potential of human natural killer cells

  2009cites this paper
• Mouse fetal and embryonic liver cells differentiate human umbilical cord blood (UCB) progenitors into CD56 negative NK cell precursors in the absence of IL-15

  2008cites this paper
• Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.

  2008cites this paper
• Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA1

  2008cites this paper
• Trogocytosis and killing of IL‐4‐polarized monocytes by autologous NK cells

  2008cites this paper
• NKG 2 D Ligand MICA theToll-Like Receptor-Induced Expression of Interaction of Monocytes with NK Cells upon

  2008cites this paper
• Adoptive Therapy with T Cells/NK Cells

  2007cites this paper
• iTRAQ is a useful method to screen for membrane-bound proteins differentially expressed in human natural killer cell types.

  2007cites this paper
• No Job Name

  2007cites this paper
• Interactions between natural killer cells, cortisol and prolactin in malaria during pregnancy.

  2006cites this paper
• Selective Expansion of Natural Killer Cells from Peripheral Blood Mononuclear Cells by K562 Cell Line and IL-2

  2006cites this paper
• Stimulating Factor and Interleukin-2 Coadministration of Recombinant Macrophage-Colony Leukemia / Lymphoma EL 4 by the Continuous Subcutaneous Antitumor Protection from the Murine T-Cell

  2006cites this paper
• Ligands for natural killer cell activating receptors are expressed upon maturation of normal myelomonocytic cells but are low in acute myeloid leukemias

  2005cites this paper
• KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation.

  2005cites this paper
• Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

  2005cites this paper
• Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

  2005cites this paper